Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Malignant Lymphoma

  Free Subscription


Articles published in Cancer

Retrieve available abstracts of 48 articles:
HTML format
Text format



Single Articles


    January 2019
  1. HAHN EE, Wu YL, Munoz-Plaza CE, Garcia Delgadillo J, et al
    Use of recommended posttreatment services for adolescent and young adult survivors of Hodgkin lymphoma.
    Cancer. 2019 Jan 8. doi: 10.1002/cncr.31953.
    PubMed     Text format     Abstract available


    December 2018
  2. RIGTER LS, Spaander MCW, Aleman BMP, Bisseling TM, et al
    High prevalence of advanced colorectal neoplasia and serrated polyposis syndrome in Hodgkin lymphoma survivors.
    Cancer. 2018 Dec 18. doi: 10.1002/cncr.31903.
    PubMed     Text format     Abstract available


  3. HOLMQVIST AS, Chen Y, Berano Teh J, Sun C, et al
    Risk of solid subsequent malignant neoplasms after childhood Hodgkin lymphoma-identification of high-risk populations to guide surveillance: A report from the Late Effects Study Group.
    Cancer. 2018 Dec 17. doi: 10.1002/cncr.31807.
    PubMed     Text format     Abstract available


  4. CALIP GS, Moran KM, Sweiss KI, Patel PR, et al
    Myelodysplastic syndrome and acute myeloid leukemia after receipt of granulocyte colony-stimulating factors in older patients with non-Hodgkin lymphoma.
    Cancer. 2018 Dec 12. doi: 10.1002/cncr.31914.
    PubMed     Text format     Abstract available


  5. HESTER LL, Park SI, Wood WA, Sturmer T, et al
    Cause-specific mortality among medicare beneficiaries with newly diagnosed non-Hodgkin lymphoma subtypes.
    Cancer. 2018 Dec 11. doi: 10.1002/cncr.31821.
    PubMed     Text format     Abstract available


    October 2018
  6. BAZARBACHI A, Boumendil A, Finel H, Mohty M, et al
    Brentuximab vedotin for recurrent Hodgkin lymphoma after allogeneic hematopoietic stem cell transplantation: A report from the EBMT Lymphoma Working Party.
    Cancer. 2018 Oct 23. doi: 10.1002/cncr.31755.
    PubMed     Text format     Abstract available


  7. PARKER PA, Banerjee SC, Matasar MJ, Bylund CL, et al
    Efficacy of a survivorship-focused consultation versus a time-controlled rehabilitation consultation in patients with lymphoma: a cluster randomized controlled trial.
    Cancer. 2018 Oct 18. doi: 10.1002/cncr.31767.
    PubMed     Text format     Abstract available


  8. KENZIK KM, Mehta A, Richman JS, Kilgore M, et al
    Congestive heart failure in older adults diagnosed with follicular lymphoma: a population-based study.
    Cancer. 2018 Oct 10. doi: 10.1002/cncr.31695.
    PubMed     Text format     Abstract available


    September 2018
  9. RIEDELL PA, Smith SM
    Double hit and double expressors in lymphoma: Definition and treatment.
    Cancer. 2018 Sep 25. doi: 10.1002/cncr.31646.
    PubMed     Text format     Abstract available


  10. HUNTINGTON SF, Hoag JR, Zhu W, Wang R, et al
    Oncologist Volume and Outcomes in Older Adults Diagnosed With Diffuse Large B Cell Lymphoma.
    Cancer. 2018 Sep 14. doi: 10.1002/cncr.31688.
    PubMed     Text format     Abstract available


    June 2018
  11. SORIGUE M, Sancho JM
    The persistent uncertainty of when to recommend allogeneic stem cell transplantation in follicular lymphoma.
    Cancer. 2018 Jun 7. doi: 10.1002/cncr.31565.
    PubMed     Text format    


  12. SUREDA A, Montoto S, Dreger P, Hamadani M, et al
    Reply to The persistent uncertainty of when to recommend allogeneic stem cell transplantation in follicular lymphoma.
    Cancer. 2018 Jun 7. doi: 10.1002/cncr.31564.
    PubMed     Text format    


    May 2018
  13. KELLER FG, Castellino SM, Chen L, Pei Q, et al
    Results of the AHOD0431 trial of response adapted therapy and a salvage strategy for limited stage, classical Hodgkin lymphoma: A report from the Children's Oncology Group.
    Cancer. 2018 May 8. doi: 10.1002/cncr.31519.
    PubMed     Text format     Abstract available


  14. ROMAGUERA JE, Wang M, Feng L, Fayad LE, et al
    Phase 2 trial of bortezomib in combination with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with bortezomib, rituximab, methotrexate, and cytarabine for untreated mantle cell lymphoma.
    Cancer. 2018 May 3. doi: 10.1002/cncr.31361.
    PubMed     Text format     Abstract available


    April 2018
  15. ARTS LPJ, Oerlemans S, Tick L, Koster A, et al
    More frequent use of health care services among distressed compared with nondistressed survivors of lymphoma and chronic lymphocytic leukemia: Results from the population-based PROFILES registry.
    Cancer. 2018 Apr 26. doi: 10.1002/cncr.31410.
    PubMed     Text format     Abstract available


  16. SMITH SM, Godfrey J, Ahn KW, DiGilio A, et al
    Autologous transplantation versus allogeneic transplantation in patients with follicular lymphoma experiencing early treatment failure.
    Cancer. 2018 Apr 12. doi: 10.1002/cncr.31374.
    PubMed     Text format     Abstract available


  17. LYNCH RC, Gopal AK
    Have we found the right patient population for transplantation in follicular lymphoma?
    Cancer. 2018 Apr 12. doi: 10.1002/cncr.31376.
    PubMed     Text format    


    March 2018
  18. GREENWELL IB, Staton AD, Lee MJ, Switchenko JM, et al
    Complex karyotype in patients with mantle cell lymphoma predicts inferior survival and poor response to intensive induction therapy.
    Cancer. 2018 Mar 26. doi: 10.1002/cncr.31328.
    PubMed     Text format     Abstract available


    February 2018

  19. Erratum: Epperla N, Maddocks KJ, Salhab M, et al. C-MYC-positive relapsed and refractory, diffuse large B-cell lymphoma: Impact of additional "hits" and outcomes with subsequent therapy. Cancer. 2017;123:4411-4418.
    Cancer. 2018;124:867.
    PubMed     Text format    


  20. SUREDA A, Zhang MJ, Dreger P, Carreras J, et al
    Allogeneic hematopoietic stem cell transplantation for relapsed follicular lymphoma: A combined analysis on behalf of the Lymphoma Working Party of the EBMT and the Lymphoma Committee of the CIBMTR.
    Cancer. 2018 Feb 9. doi: 10.1002/cncr.31264.
    PubMed     Text format     Abstract available


    December 2017
  21. PRINTZ C
    First person: Julie Vose, MD, MBA: The lymphoma specialist is focused on patients as well as organizational leadership.
    Cancer. 2017;123:4749.
    PubMed     Text format    


    November 2017
  22. MYERS RM, Hill BT, Shaw BE, Kim S, et al
    Long-term outcomes among 2-year survivors of autologous hematopoietic cell transplantation for Hodgkin and diffuse large b-cell lymphoma.
    Cancer. 2017 Nov 10. doi: 10.1002/cncr.31114.
    PubMed     Text format     Abstract available


  23. ARMENIAN SH, Mertens L, Slorach C, Venkataraman K, et al
    Prevalence of anthracycline-related cardiac dysfunction in long-term survivors of adult-onset lymphoma.
    Cancer. 2017 Nov 7. doi: 10.1002/cncr.31110.
    PubMed     Text format     Abstract available


  24. AMMANN EM, Drake MT, Haraldsson B, Wallace RB, et al
    Incidence of hematologic malignancy and cause-specific mortality in the Women's Health Initiative randomized controlled trial of calcium and vitamin D supplementation.
    Cancer. 2017;123:4168-4177.
    PubMed     Text format     Abstract available


  25. FRICK MA, Vachani CC, Bach C, Hampshire MK, et al
    Survivorship and the chronic cancer patient: Patterns in treatment-related effects, follow-up care, and use of survivorship care plans.
    Cancer. 2017;123:4268-4276.
    PubMed     Text format     Abstract available


    October 2017
  26. MAJZNER RG, Simon JS, Grosso JF, Martinez D, et al
    Assessment of programmed death-ligand 1 expression and tumor-associated immune cells in pediatric cancer tissues.
    Cancer. 2017;123:3807-3815.
    PubMed     Text format     Abstract available


    September 2017
  27. HAN CH, Batchelor TT
    Diagnosis and management of primary central nervous system lymphoma.
    Cancer. 2017 Sep 26. doi: 10.1002/cncr.30965.
    PubMed     Text format     Abstract available


  28. EHRHARDT MJ, Mulrooney DA, Li C, Baassiri MJ, et al
    Neurocognitive, psychosocial, and quality-of-life outcomes in adult survivors of childhood non-Hodgkin lymphoma.
    Cancer. 2017 Sep 15. doi: 10.1002/cncr.31019.
    PubMed     Text format     Abstract available


  29. HENDERSON TO, Parsons SK, Wroblewski KE, Chen L, et al
    Outcomes in adolescents and young adults with Hodgkin lymphoma treated on US cooperative group protocols: An adult intergroup (E2496) and Children's Oncology Group (COG AHOD0031) comparative analysis.
    Cancer. 2017 Sep 13. doi: 10.1002/cncr.30979.
    PubMed     Text format     Abstract available


    August 2017
  30. MEDHANIE GA, Fedewa SA, Adissu H, DeSantis CE, et al
    Cancer incidence profile in sub-Saharan African-born blacks in the United States: Similarities and differences with US-born non-Hispanic blacks.
    Cancer. 2017;123:3116-3124.
    PubMed     Text format     Abstract available


    July 2017
  31. YANIK EL, Shiels MS, Smith JM, Clarke CA, et al
    Contribution of solid organ transplant recipients to the pediatric non-hodgkin lymphoma burden in the United States.
    Cancer. 2017 Jul 31. doi: 10.1002/cncr.30923.
    PubMed     Text format     Abstract available


  32. EPPERLA N, Maddocks KJ, Salhab M, Chavez JC, et al
    C-MYC-positive relapsed and refractory, diffuse large B-cell lymphoma: Impact of additional "hits" and outcomes with subsequent therapy.
    Cancer. 2017 Jul 27. doi: 10.1002/cncr.30895.
    PubMed     Text format     Abstract available


  33. ALVAREZ E, Keegan T, Johnston EE, Haile R, et al
    Adolescent and young adult oncology patients: Disparities in access to specialized cancer centers.
    Cancer. 2017;123:2516-2523.
    PubMed     Text format     Abstract available


    June 2017
  34. HUI L, von Keudell G, Wang R, Zeidan AM, et al
    Cost-effectiveness analysis of consolidation with brentuximab vedotin for high-risk Hodgkin lymphoma after autologous stem cell transplantation.
    Cancer. 2017 Jun 22. doi: 10.1002/cncr.30818.
    PubMed     Text format     Abstract available


  35. CARBONE A, Gloghini A
    Hodgkin lymphoma classification: Are we at a crossroads?
    Cancer. 2017 Jun 16. doi: 10.1002/cncr.30824.
    PubMed     Text format    


  36. PROVENCIO M, Royuela A, Torrente M, Pollan M, et al
    Prognostic value of event-free survival at 12 and 24 months and long-term mortality for non-Hodgkin follicular lymphoma patients: A study report from the Spanish Lymphoma Oncology Group.
    Cancer. 2017 Jun 13. doi: 10.1002/cncr.30795.
    PubMed     Text format     Abstract available


    May 2017
  37. RAJAGOPAL R, Miles GCP, Kotecha RS
    High-dose chemotherapy with thiotepa, busulfan, and cyclophosphamide and autologous stem cell transplantation for pediatric primary central nervous system lymphoma in first complete remission.
    Cancer. 2017 May 23. doi: 10.1002/cncr.30768.
    PubMed     Text format    


  38. LIN CJ, Vader JM, Slade M, DiPersio JF, et al
    Cardiomyopathy in patients after posttransplant cyclophosphamide-based hematopoietic cell transplantation.
    Cancer. 2017;123:1800-1809.
    PubMed     Text format     Abstract available


  39. LEHMANN V, Tuinman MA, Keim MC, Winning AM, et al
    Psychosexual development and satisfaction in long-term survivors of childhood cancer: Neurotoxic treatment intensity as a risk indicator.
    Cancer. 2017;123:1869-1876.
    PubMed     Text format     Abstract available


  40. GHAZAWI FM, Netchiporouk E, Rahme E, Tsang M, et al
    Comprehensive analysis of cutaneous T-cell lymphoma (CTCL) incidence and mortality in Canada reveals changing trends and geographic clustering for this malignancy.
    Cancer. 2017 May 10. doi: 10.1002/cncr.30758.
    PubMed     Text format     Abstract available


  41. KOFF JL, Flowers CR
    Prognostic modeling in diffuse large B-cell lymphoma in the era of immunochemotherapy: Where do we go from here?
    Cancer. 2017 May 2. doi: 10.1002/cncr.30740.
    PubMed     Text format    


  42. HOWLADER N, Mariotto AB, Besson C, Suneja G, et al
    Cancer-specific mortality, cure fraction, and noncancer causes of death among diffuse large B-cell lymphoma patients in the immunochemotherapy era.
    Cancer. 2017 May 2. doi: 10.1002/cncr.30739.
    PubMed     Text format     Abstract available


    April 2017
  43. VARGO JA, Patel A, Glaser SM, Balasubramani GK, et al
    The impact of the omission or inadequate dosing of radiotherapy in extranodal natural killer T-cell lymphoma, nasal type, in the United States.
    Cancer. 2017 Apr 5. doi: 10.1002/cncr.30697.
    PubMed     Text format     Abstract available


  44. DEFILIPP Z, Li S, El-Jawahri A, Armand P, et al
    High-dose chemotherapy with thiotepa, busulfan, and cyclophosphamide and autologous stem cell transplantation for patients with primary central nervous system lymphoma in first complete remission.
    Cancer. 2017 Apr 3. doi: 10.1002/cncr.30695.
    PubMed     Text format     Abstract available


    February 2017
  45. MANYAM BV, Garsa AA, Chin RI, Reddy CA, et al
    A multi-institutional comparison of outcomes of immunosuppressed and immunocompetent patients treated with surgery and radiation therapy for cutaneous squamous cell carcinoma of the head and neck.
    Cancer. 2017 Feb 7. doi: 10.1002/cncr.30601.
    PubMed     Text format     Abstract available



  46. First Person: Clara Bloomfield, MD.
    Cancer. 2017;123:369-370.
    PubMed     Text format    


    January 2017
  47. EL-JAWAHRI A, Chen YB, Brazauskas R, He N, et al
    Impact of pre-transplant depression on outcomes of allogeneic and autologous hematopoietic stem cell transplantation.
    Cancer. 2017 Jan 19. doi: 10.1002/cncr.30546.
    PubMed     Text format     Abstract available


    June 2016
  48. OLSZEWSKI AJ, Fallah J, Castillo JJ
    Human immunodeficiency virus-associated lymphomas in the antiretroviral therapy era: Analysis of the National Cancer Data Base.
    Cancer. 2016 Jun 23. doi: 10.1002/cncr.30112.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Malignant Lymphoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: